{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:02:07Z","timestamp":1793084527877,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prime editing is a versatile genome editing technology that circumvents the need for DNA double-strand break formation and homology-directed repair, making it particularly suitable for in vivo correction of pathogenic mutations. Here we developed liver-specific prime editing approaches with temporally restricted prime editor (PE) expression. We first established a dual-delivery approach where the prime editor guide RNA is continuously expressed from adeno-associated viral vectors and only the PE is transiently delivered as nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNP). This strategy achieved 26.2% editing with PEmax and 47.4% editing with PE7 at the\n                    <jats:italic>Dnmt1<\/jats:italic>\n                    locus using a single 2\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    dose of mRNA\u2013LNP. When targeting the pathogenic\n                    <jats:italic>Pah<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>enu2<\/jats:italic>\n                    <\/jats:sup>\n                    mutation in a phenylketonuria mouse model, gene correction rates reached 4.3% with PEmax and 20.7% with PE7 after three doses of 2\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    mRNA\u2013LNP, effectively reducing blood\n                    <jats:sc>l<\/jats:sc>\n                    -phenylalanine levels from over 1,500\u2009\u00b5mol\u2009l\n                    <jats:sup>\u22121<\/jats:sup>\n                    to below the therapeutic threshold of 360\u2009\u00b5mol\u2009l\n                    <jats:sup>\u22121<\/jats:sup>\n                    . Encouraged by the high efficiency of PE7, we next explored a simplified approach where PE7 mRNA was co-delivered with synthetic prime editor guide RNAs encapsulated in LNP. This strategy yielded 35.9% editing after two doses of RNA\u2013LNP at the\n                    <jats:italic>Dnmt1<\/jats:italic>\n                    locus and 8.0% editing after three doses of RNA\u2013LNP at the\n                    <jats:italic>Pah<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>enu2<\/jats:italic>\n                    <\/jats:sup>\n                    locus, again reducing\n                    <jats:sc>l<\/jats:sc>\n                    -phenylalanine levels below 360\u2009\u00b5mol\u2009l\n                    <jats:sup>\u22121<\/jats:sup>\n                    . These findings highlight the therapeutic potential of mRNA\u2013LNP-based prime editing for treating phenylketonuria and other genetic liver diseases, offering a scalable and efficient platform for future clinical translation.\n                  <\/jats:p>","DOI":"10.1038\/s41551-025-01399-4","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T06:15:58Z","timestamp":1747721758000},"page":"1705-1718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Treatment of a metabolic liver disease in mice with a transient prime editing approach"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7799-2413","authenticated-orcid":false,"given":"Tanja","family":"Rothgangl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-8333","authenticated-orcid":false,"given":"Andr\u00e1s","family":"T\u00e1las","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3005-2684","authenticated-orcid":false,"given":"Eleonora I.","family":"Ioannidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanik","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e","family":"B\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina Andrea","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5993-9985","authenticated-orcid":false,"given":"Lukas","family":"Schmidheini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woohyun J.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo J. C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H. Y.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7393-4398","authenticated-orcid":false,"given":"Kim F.","family":"Marquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Schwerdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Rimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Faccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-1493","authenticated-orcid":false,"given":"Hiromi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-987X","authenticated-orcid":false,"given":"M\u00e1t\u00e9","family":"Vadovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cremonesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter Istv\u00e1n","family":"Kulcs\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-086X","authenticated-orcid":false,"given":"Beat","family":"Th\u00f6ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-7140","authenticated-orcid":false,"given":"Manfred","family":"Kopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-091X","authenticated-orcid":false,"given":"Johannes","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-6242","authenticated-orcid":false,"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4083-5251","authenticated-orcid":false,"given":"Ying K.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-2953","authenticated-orcid":false,"given":"Gerald","family":"Schwank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"1399_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau, N., Van Spronsen, F. J. & Levy, H. L. Phenylketonuria. Lancet 376, 1417\u20131427 (2010).","journal-title":"Lancet"},{"key":"1399_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/GIM.0b013e3182141b48","volume":"13","author":"JJ Mitchell","year":"2011","unstructured":"Mitchell, J. J., Trakadis, Y. J. & Scriver, C. R. Phenylalanine hydroxylase deficiency. Genet. Med. 13, 607\u2013617 (2011).","journal-title":"Genet. Med."},{"key":"1399_CR3","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJM198012113032404","volume":"303","author":"CR Scriver","year":"1980","unstructured":"Scriver, C. R. & Clow, C. L. Phenylketonuria: epitome of human biochemical genetics. N. Engl. J. Med. 303, 1394\u20131400 (1980).","journal-title":"N. Engl. J. Med."},{"key":"1399_CR4","doi-asserted-by":"crossref","unstructured":"Hydery, T. & Coppenrath, V. A. A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria. Drug Target Insights 13, 1177392819857089 (2019).","DOI":"10.1177\/1177392819857089"},{"key":"1399_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jimd.12651","volume":"47","author":"M Martinez","year":"2024","unstructured":"Martinez, M., Harding, C. O., Schwank, G. & Th\u00f6ny, B. State-of-the-art 2023 on gene therapy for phenylketonuria. J. Inherit. Metab. Dis. 47, 80\u201392 (2024).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1399_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin, H. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328\u2013333 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR7","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/genetics\/134.4.1205","volume":"134","author":"A Shedlovsky","year":"1993","unstructured":"Shedlovsky, A., McDonald, J. D., Symula, D. & Dove, W. F. Mouse models of human phenylketonuria. Genetics 134, 1205\u20131210 (1993).","journal-title":"Genetics"},{"key":"1399_CR8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","volume":"24","author":"L Villiger","year":"2018","unstructured":"Villiger, L. et al. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice. Nat. Med. 24, 1519\u20131525 (2018).","journal-title":"Nat. Med."},{"key":"1399_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","volume":"17","author":"DY Richards","year":"2019","unstructured":"Richards, D. Y. et al. AAV-mediated CRISPR\/Cas9 gene editing in murine phenylketonuria. Mol. Ther. Methods Clin. Dev. 17, 234\u2013245 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1399_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.omtm.2022.01.001","volume":"24","author":"L Zhou","year":"2022","unstructured":"Zhou, L. et al. A universal strategy for AAV delivery of base editors to correct genetic point mutations in neonatal PKU mice. Mol. Ther. Methods Clin. Dev. 24, 230\u2013240 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1399_CR11","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.ajhg.2023.10.005","volume":"110","author":"DL Brooks","year":"2023","unstructured":"Brooks, D. L. et al. Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical need. Am. J. Hum. Genet 110, 2003\u20132014 (2023).","journal-title":"Am. J. Hum. Genet"},{"key":"1399_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39246-2","volume":"14","author":"DL Brooks","year":"2023","unstructured":"Brooks, D. L. et al. Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing. Nat. Commun. 14, 3451 (2023).","journal-title":"Nat. Commun."},{"key":"1399_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"1399_CR14","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.ymthe.2022.01.005","volume":"30","author":"C Zheng","year":"2022","unstructured":"Zheng, C. et al. A flexible split prime editor using truncated reverse transcriptase improves dual-AAV delivery in mouse liver. Mol. Ther. 30, 1343\u20131351 (2022).","journal-title":"Mol. Ther."},{"key":"1399_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ymthe.2021.07.011","volume":"30","author":"S Zhi","year":"2022","unstructured":"Zhi, S. et al. Dual-AAV delivering split prime editor system for in vivo genome editing. Mol. Ther. 30, 283\u2013294 (2022).","journal-title":"Mol. Ther."},{"key":"1399_CR16","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","volume":"29","author":"GA Newby","year":"2021","unstructured":"Newby, G. A. & Liu, D. R. In vivo somatic cell base editing and prime editing. Mol. Ther. 29, 3107\u20133124 (2021).","journal-title":"Mol. Ther."},{"key":"1399_CR17","doi-asserted-by":"publisher","first-page":"9238","DOI":"10.1126\/scitranslmed.abl9238","volume":"14","author":"D B\u00f6ck","year":"2022","unstructured":"B\u00f6ck, D. et al. In vivo prime editing of a metabolic liver disease in mice. Sci. Transl. Med. 14, 9238 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1399_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22295-w","volume":"12","author":"P Liu","year":"2021","unstructured":"Liu, P. et al. Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice. Nat. Commun. 12, 2121 (2021).","journal-title":"Nat. Commun."},{"key":"1399_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1089\/genbio.2023.0045","volume":"2","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. In vivo prime editing by lipid nanoparticle co-delivery of chemically modified pegRNA and prime editor mRNA. GEN Biotechnol. 2, 490\u2013502 (2023).","journal-title":"GEN Biotechnol."},{"key":"1399_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","volume":"42","author":"JR Davis","year":"2023","unstructured":"Davis, J. R. et al. Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nat. Biotechnol. 42, 253\u2013264 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220776","volume":"220","author":"H Qin","year":"2023","unstructured":"Qin, H. et al. Vision rescue via unconstrained in vivo prime editing in degenerating neural retinas. J. Exp. Med. 220, e20220776 (2023).","journal-title":"J. Exp. Med."},{"key":"1399_CR22","first-page":"2085","volume":"141","author":"C Li","year":"2023","unstructured":"Li, C. et al. In vivo HSC prime editing rescues sickle cell disease in a mouse model. Blood 141, 2085\u20132099 (2023).","journal-title":"Blood"},{"key":"1399_CR23","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635\u20135652.e29 (2021).","journal-title":"Cell"},{"key":"1399_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","volume":"40","author":"JW Nelson","year":"2021","unstructured":"Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402\u2013410 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR25","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/s41587-022-01613-7","volume":"41","author":"N Mathis","year":"2023","unstructured":"Mathis, N. et al. Predicting prime editing efficiency and product purity by deep learning. Nat. Biotechnol. 41, 1151\u20131159 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/hep.27104","volume":"60","author":"HM Viecelli","year":"2014","unstructured":"Viecelli, H. M. et al. Treatment of phenylketonuria using minicircle-based naked-DNA gene transfer to murine liver. Hepatology 60, 1035\u20131043 (2014).","journal-title":"Hepatology"},{"key":"1399_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-7-17","volume":"7","author":"JH Choi","year":"2014","unstructured":"Choi, J. H. et al. Optimization of AAV expression cassettes to improve packaging capacity and transgene expression in neurons. Mol. Brain 7, 17 (2014).","journal-title":"Mol. Brain"},{"key":"1399_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","volume":"39","author":"T Rothgangl","year":"2021","unstructured":"Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949\u2013957 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg, A. M. J. et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J. Rare Dis. 12, 162 (2017).","journal-title":"Orphanet J. Rare Dis."},{"key":"1399_CR30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1399_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis, A. Novartis confirms deaths of two patients treated with gene therapy Zolgensma. Hum. Gene Ther. 33, 842\u2013844 (2022).","journal-title":"Hum. Gene Ther."},{"key":"1399_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434 (2021).","journal-title":"Nature"},{"key":"1399_CR33","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn, J. D. et al. A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227\u20132235 (2018).","journal-title":"Cell Rep."},{"key":"1399_CR34","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/nbt.4005","volume":"35","author":"H Yin","year":"2017","unstructured":"Yin, H. et al. structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179\u20131187 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-26714-w","volume":"12","author":"E Kenjo","year":"2021","unstructured":"Kenjo, E. et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat. Commun. 12, 1\u201313 (2021).","journal-title":"Nat. Commun."},{"key":"1399_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41551-020-00671-z","volume":"5","author":"L Villiger","year":"2021","unstructured":"Villiger, L. et al. In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA. Nat. Biomed. Eng. 5, 179\u2013189 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"1399_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1399_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","volume":"217","author":"O Andries","year":"2015","unstructured":"Andries, O. et al. N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217, 337\u2013344 (2015).","journal-title":"J. Control. Release"},{"key":"1399_CR39","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1021\/acs.biochem.1c00768","volume":"62","author":"DE Ryan","year":"2023","unstructured":"Ryan, D. E. et al. Phosphonoacetate modifications enhance the stability and editing yields of guide RNAs for Cas9 editors. Biochemistry 62, 3512\u20133520 (2023).","journal-title":"Biochemistry"},{"key":"1399_CR40","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41587-023-01947-w","volume":"42","author":"B Liu","year":"2024","unstructured":"Liu, B. et al. Targeted genome editing with a DNA-dependent DNA polymerase and exogenous DNA-containing templates. Nat. Biotechnol. 42, 1039\u20131045 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR41","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41587-024-02266-4","volume":"43","author":"S Levesque","year":"2025","unstructured":"Levesque, S., Cosentino, A., Verma, A., Genovese, P. & Bauer, D. E. Enhancing prime editing in hematopoietic stem and progenitor cells by modulating nucleotide metabolism. Nat. Biotechnol. 43, 534\u2013538 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR42","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41587-024-02405-x","volume":"43","author":"P Liu","year":"2025","unstructured":"Liu, P. et al. Increasing intracellular dNTP levels improves prime editing efficiency. Nat. Biotechnol. 43, 539\u2013544 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02268-2","author":"N Mathis","year":"2024","unstructured":"Mathis, N. et al. Machine learning prediction of prime editing efficiency across diverse chromatin contexts. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02268-2 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR44","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41586-024-07259-6","volume":"628","author":"J Yan","year":"2024","unstructured":"Yan, J. et al. Improving prime editing with an endogenous small RNA-binding protein. Nature 628, 639\u2013647 (2024).","journal-title":"Nature"},{"key":"1399_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","volume":"159","author":"D Witzigmann","year":"2020","unstructured":"Witzigmann, D. et al. Lipid nanoparticle technology for therapeutic gene regulation in the liver. Adv. Drug Deliv. Rev. 159, 344\u2013363 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1399_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xhgg.2023.100253","volume":"5","author":"DL Brooks","year":"2024","unstructured":"Brooks, D. L. et al. A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variant. Hum. Genet. Genomics Adv. 5, 100253 (2024).","journal-title":"Hum. Genet. Genomics Adv."},{"key":"1399_CR47","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/jimd.12392","volume":"44","author":"RA Kaiser","year":"2021","unstructured":"Kaiser, R. A. et al. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model. J. Inherit. Metab. Dis. 44, 1369\u20131381 (2021).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1399_CR48","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1053\/j.gastro.2009.05.044","volume":"137","author":"AW Duncan","year":"2009","unstructured":"Duncan, A. W., Dorrell, C. & Grompe, M. Stem cells and liver regeneration. Gastroenterology 137, 466 (2009).","journal-title":"Gastroenterology"},{"key":"1399_CR49","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/s41596-020-00465-2","volume":"16","author":"RT Walton","year":"2021","unstructured":"Walton, R. T., Hsu, J. Y., Joung, J. K. & Kleinstiver, B. P. Scalable characterization of the PAM requirements of CRISPR\u2013Cas enzymes using HT-PAMDA. Nat. Protoc. 16, 1511\u20131547 (2021).","journal-title":"Nat. Protoc."},{"key":"1399_CR50","doi-asserted-by":"publisher","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","volume":"79","author":"JC Grieger","year":"2005","unstructured":"Grieger, J. C. & Samulski, R. J. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J. Virol. 79, 9933 (2005).","journal-title":"J. Virol."},{"key":"1399_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc9937","volume":"8","author":"K van de Ven","year":"2022","unstructured":"van de Ven, K. et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Sci. Adv. 8, eadc9937 (2022).","journal-title":"Sci. Adv."},{"key":"1399_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1399_CR53","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2019.03.003","volume":"27","author":"A Conway","year":"2019","unstructured":"Conway, A. et al. Non-viral delivery of Zinc Finger Nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets. Mol. Ther. 27, 866\u2013877 (2019).","journal-title":"Mol. Ther."},{"key":"1399_CR54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","volume":"37","author":"K Clement","year":"2019","unstructured":"Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224\u2013226 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1399_CR55","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ymgme.2011.12.025","volume":"105","author":"C Heintz","year":"2012","unstructured":"Heintz, C., Troxler, H., Martinez, A., Th\u00f6ny, B. & Blau, N. Quantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. Mol. Genet Metab. 105, 559\u2013565 (2012).","journal-title":"Mol. Genet Metab."},{"key":"1399_CR56","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"1399_CR57","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley, J. et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet. Med. 16, 188\u2013200 (2014).","journal-title":"Genet. Med."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01399-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01399-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01399-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:03:06Z","timestamp":1760659386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01399-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1399"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01399-4","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K.T., P.J.C.L. and S.H.Y.F. are employees of Acuitas Therapeutics. G.S. is a scientific advisor of Prime Medicine. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}